[HTML][HTML] Emerging therapies for acute myelogenus leukemia patients targeting apoptosis and mitochondrial metabolism
G Castelli, E Pelosi, U Testa - Cancers, 2019 - mdpi.com
Acute Myelogenous Leukemia (AML) is a malignant disease of the hematopoietic cells,
characterized by impaired differentiation and uncontrolled clonal expansion of myeloid …
characterized by impaired differentiation and uncontrolled clonal expansion of myeloid …
Dihydroorotate dehydrogenase inhibitors promote cell cycle arrest and disrupt mitochondria bioenergetics in Ramos cells
MFA Kadir, S Othman, K Nellore - Current Pharmaceutical …, 2020 - ingentaconnect.com
Background: The re-emerging of targeting Dihydroorotate Dehydrogenase (DHODH) in
cancer treatment particularly Acute Myelogenous Leukemia (AML) has corroborated the …
cancer treatment particularly Acute Myelogenous Leukemia (AML) has corroborated the …
Functional Genomics of Mammalian Innate Immunity
MC Kiritsy - 2020 - repository.escholarship.umassmed …
The breadth of genetic diversity in the mammalian immune response stands out amongst the
ubiquity of variation seen in the genome, evidence that microbial infections have been a …
ubiquity of variation seen in the genome, evidence that microbial infections have been a …